Rilutek (riluzole) has been shown to be effective in treating amyotrophic lateral sclerosis (ALS), with clinical studies demonstrating its impact on survival and disease progression. Clinical trials indicate that it may extend survival by approximately 2 to 3 months compared to placebo, with some studies suggesting a potential increase of 6 to 19 months in real-world settings.